Cargando…
Emerging Monoclonal Antibody Therapy for the Treatment of Acute Lymphoblastic Leukemia
The treatment of adults with ALL has undergone tremendous progress over the past 15 years. The advances have been particularly marked with B-lineage ALL. The development of bispecific antibodies directed against CD19 ushered in a new era in overcoming persistent minimal disease in newly diagnosed AL...
Autores principales: | Abuasab, Tareq, Rowe, Jacob, Tvito, Ariella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536880/ https://www.ncbi.nlm.nih.gov/pubmed/34703207 http://dx.doi.org/10.2147/BTT.S290294 |
Ejemplares similares
-
Infectious complications during monoclonal antibodies treatments and cell therapies in Acute Lymphoblastic Leukemia
por: Quattrone, Martina, et al.
Publicado: (2023) -
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
por: Guerra, Veronica A., et al.
Publicado: (2019) -
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
por: Conde-Royo, Diego, et al.
Publicado: (2020) -
Pathogenesis and prognostication in acute lymphoblastic leukemia
por: Zuckerman, Tsila, et al.
Publicado: (2014) -
Recent updates for antibody therapy for acute lymphoblastic leukemia
por: Li, Le, et al.
Publicado: (2020)